BNT24002: Advanced Treatment for Lupus Nephritis (LN)

Sublingual Cladribine Formulation Designed for High Bioavailability

BioNxt’s BNT24002 is an innovative sublingual thin film designed specifically for lupus nephritis (LN), a severe and complex autoimmune condition. By leveraging advanced sublingual technology, BNT24002 enables high absorption directly through the mucosa, offering a targeted, patient-friendly solution for LN patients who struggle with low bioavailability from traditional oral medications.

Why BNT24002?

• Improved Absorption: BNT24002’s sublingual delivery bypasses the gastrointestinal system, avoiding first-pass metabolism in the liver. This leads to higher bioavailability, faster onset, and more consistent therapeutic effects.
• Patient Compliance: Many LN patients face challenges with conventional oral therapies due to low absorption and side effects. BNT24002’s dissolvable film provides a simpler, non-invasive option that is easy to administer and may lead to better adherence.
• Focused on Orphan Disease: Lupus nephritis is an orphan disease, with an estimated 80,000–100,000 patients in the U.S. alone, and limited treatment options. BNT24002 is designed to meet this urgent need, bringing a specialized therapy to a highly underserved patient group.

Addressing the Growing Need in Lupus Nephritis

With the lupus nephritis treatment market projected to grow from $2 billion to $3.2 billion by 2032, there is a critical need for therapies that offer high bioavailability and minimal side effects. BNT24002 is well-positioned to address this gap, providing an optimized therapy that enhances treatment efficacy and patient quality of life.

Product Features

• Convenient & Non-Invasive: The sublingual film dissolves quickly in the mouth, delivering the medication without the need for injections or tablets.
• Consistent Absorption: BNT24002 is designed for high absorption through the sublingual mucosa, avoiding issues related to food intake or gastrointestinal factors.
• Reduced Dose Potential: Improved bioavailability may allow for lower dosing, potentially reducing the risk of side effects.
• Targeted for Orphan Status: Positioned as an orphan drug, BNT24002 is eligible for extended market exclusivity, offering a competitive advantage.

Next Steps for BNT24002

BioNxt is advancing BNT24002 toward pre-clinical and clinical studies, with plans to explore its safety and pharmacokinetics in animal models. Following these studies, we aim to accelerate the regulatory path for BNT24002 to provide LN patients with this much-needed solution.

Learn More About BNT24002

For more details on BNT24002 and our commitment to advancing lupus nephritis treatment, please contact us or follow our progress through upcoming development milestones. Together, we are reimagining treatment possibilities for those living with LN.